| pubmed-article:18317076 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0078058 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C1256770 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C1135135 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0018284 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:18317076 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:18317076 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18317076 | pubmed:dateCreated | 2008-3-4 | lld:pubmed |
| pubmed-article:18317076 | pubmed:abstractText | A 37-year-old female never smoker with metastatic large cell carcinoma of the lung had a partial response to a second line palliative therapy with the EGF-R tyrosine kinase inhibitor erlotinib after platinum based first line therapy failed. Molecular analysis of the primary and a liver metastasis did neither find any EGF-R mutation nor an EGF-R amplification. However, both the primary and the metastasis showed an increased gene expression of vascular-endothelial growth factor-A in contrast to normal tissue, which was confirmed by immunohistochemistry. To our knowledge, this is the first report about a high vascular-endothelial growth factor-A expression in the tumor of a patient responding to an EGF-R inhibitor postulating that there might be a link between both tyrosine kinase pathways. | lld:pubmed |
| pubmed-article:18317076 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18317076 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18317076 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18317076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18317076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18317076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18317076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18317076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18317076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18317076 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18317076 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:18317076 | pubmed:issn | 1556-1380 | lld:pubmed |
| pubmed-article:18317076 | pubmed:author | pubmed-author:HahnEckhart... | lld:pubmed |
| pubmed-article:18317076 | pubmed:author | pubmed-author:MurraySamuelS | lld:pubmed |
| pubmed-article:18317076 | pubmed:author | pubmed-author:BruecklWolfga... | lld:pubmed |
| pubmed-article:18317076 | pubmed:author | pubmed-author:WiestGunther... | lld:pubmed |
| pubmed-article:18317076 | pubmed:author | pubmed-author:SchoeberlAnja... | lld:pubmed |
| pubmed-article:18317076 | pubmed:author | pubmed-author:WirtzRalph... | lld:pubmed |
| pubmed-article:18317076 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18317076 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:18317076 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18317076 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18317076 | pubmed:pagination | 314-6 | lld:pubmed |
| pubmed-article:18317076 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:meshHeading | pubmed-meshheading:18317076... | lld:pubmed |
| pubmed-article:18317076 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18317076 | pubmed:articleTitle | Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). | lld:pubmed |
| pubmed-article:18317076 | pubmed:affiliation | Department of Medicine 1, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany. wolfgang.brueckl@uk-erlangen.de | lld:pubmed |
| pubmed-article:18317076 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18317076 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:18317076 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1956 | entrezgene:pubmed | pubmed-article:18317076 | lld:entrezgene |
| entrez-gene:7422 | entrezgene:pubmed | pubmed-article:18317076 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18317076 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18317076 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18317076 | lld:pubmed |
